Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.
SNP
UGT2B7
escalation
genotype
toxicity
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
13
10
2020
revised:
22
02
2021
accepted:
01
03
2021
pubmed:
10
4
2021
medline:
5
2
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7). Patients homozygous for the minor allele (CC) in the UGT2B7 -161 promoter polymorphism have lower clearance and significantly higher rates of leukopenia compared to wild-type homozygote (TT) or heterozygote (CT) patients. This study was designed to determine if TT and CT genotype patients could tolerate a higher epirubicin dose compared to CC genotype patients. We studied women with histologically confirmed non-metastatic, invasive breast cancer who were scheduled to receive at least three cycles of FE Forty-five patients were enrolled (10 CC, 21 CT, and 14 TT genotypes) and received 100 mg/m Pharmacogenetically guided epirubicin dosing is well tolerated and allowed dose escalation without increased toxicity.
Sections du résumé
BACKGROUND
Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7). Patients homozygous for the minor allele (CC) in the UGT2B7 -161 promoter polymorphism have lower clearance and significantly higher rates of leukopenia compared to wild-type homozygote (TT) or heterozygote (CT) patients. This study was designed to determine if TT and CT genotype patients could tolerate a higher epirubicin dose compared to CC genotype patients.
PATIENTS AND METHODS
We studied women with histologically confirmed non-metastatic, invasive breast cancer who were scheduled to receive at least three cycles of FE
RESULTS
Forty-five patients were enrolled (10 CC, 21 CT, and 14 TT genotypes) and received 100 mg/m
CONCLUSION
Pharmacogenetically guided epirubicin dosing is well tolerated and allowed dose escalation without increased toxicity.
Identifiants
pubmed: 33832852
pii: S1526-8209(21)00056-2
doi: 10.1016/j.clbc.2021.03.001
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Epirubicin
3Z8479ZZ5X
Cyclophosphamide
8N3DW7272P
UGT2B7 protein, human
EC 2.4.1.-
Glucuronosyltransferase
EC 2.4.1.17
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e584-e593Informations de copyright
Copyright © 2021. Published by Elsevier Inc.